Table of Content

1 INTRODUCTION 25
1.1 STUDY OBJECTIVES 25
1.2 MARKET DEFINITION 25
1.3 STUDY SCOPE 26
1.3.1 MARKET SEGMENTATION & GEOGRAPHICAL SPREAD 26
1.3.2 INCLUSIONS & EXCLUSIONS 27
1.3.3 YEARS CONSIDERED 28
1.3.4 CURRENCY CONSIDERED 28
1.4 STAKEHOLDERS 28
1.5 SUMMARY OF CHANGES 29
2 RESEARCH METHODOLOGY 30
2.1 RESEARCH DATA 30
2.1.1 SECONDARY DATA 30
2.1.1.1 Key sources of secondary data 31
2.1.1.2 Key data from secondary sources 31
2.1.2 PRIMARY DATA 32
2.1.2.1 Objectives of primary research 32
2.1.2.2 Key data from primary sources 33
2.1.2.3 Insights from primary experts 33
2.1.3 MARKET SIZE ESTIMATION 34
2.1.3.1 Supply-side analysis 34
2.1.3.2 Bottom-up approach (demand-side analysis) 35
2.1.3.3 Top-down approach (parent market assessment) 36
2.2 DATA TRIANGULATION 40
2.3 STUDY ASSUMPTIONS 41
2.4 RISK ANALYSIS 41
2.5 RESEARCH LIMITATIONS 42
2.5.1 METHODOLOGY-RELATED LIMITATIONS 42
2.5.2 SCOPE-RELATED LIMITATIONS 42
3 EXECUTIVE SUMMARY 43
4 PREMIUM INSIGHTS 47
4.1 SMART PILLS MARKET OVERVIEW 47
4.2 NORTH AMERICA: SMART PILLS MARKET, BY APPLICATION AND COUNTRY, 2023 48
4.3 SMART PILLS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 49
4.4 SMART PILLS MARKET: REGIONAL MIX 49
4.5 SMART PILLS MARKET: DEVELOPED VS. EMERGING MARKETS 50
5 MARKET OVERVIEW 51
5.1 INTRODUCTION 51
5.2 MARKET DYNAMICS 51
5.2.1 DRIVERS 52
5.2.1.1 Rising demand for non-invasive diagnostic monitoring devices 52
5.2.1.2 Technological advancements in capsule endoscopy 53
5.2.1.3 Increasing incidence of colon cancer 54
5.2.2 RESTRAINTS 54
5.2.2.1 High R&D costs for technological developments and advancements 54
5.2.2.2 Low accuracy and reliability of sensors and cameras in smart pills 55
5.2.3 OPPORTUNITIES 55
5.2.3.1 Innovations in sensor technologies and wireless communication 55
5.2.3.2 Rising need for rapid drug delivery and development 55
5.2.4 CHALLENGES 56
5.2.4.1 Increased patient privacy and data security concerns 56
5.2.4.2 Shortage of skilled healthcare professionals 57
5.3 INDUSTRY TRENDS 58
5.3.1 ADVANCEMENTS IN SENSOR TECHNOLOGIES 58
5.3.2 INTEGRATION WITH AI AND ML 58
5.3.3 INTEGRATION WITH WEARABLE DEVICES 58
5.4 TECHNOLOGY ANALYSIS 59
5.4.1 KEY TECHNOLOGIES 59
5.4.1.1 Wireless communication systems 59
5.4.1.2 Sensor technologies 59
5.4.1.3 Self-powered ingestible smart pills 60
5.4.1.4 Adaptive frame rate technologies 60
5.4.1.5 iMAG 61
5.4.1.6 AI and ML 62
5.4.2 COMPLEMENTARY TECHNOLOGIES 62
5.4.2.1 Robotic technologies 62
5.4.2.2 Data analytics 63
5.4.3 ADJACENT TECHNOLOGIES 63
5.4.3.1 IoT 63
5.4.3.2 Cloud computing 63
5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 63
5.6 PIPELINE ANALYSIS 64
5.7 PORTER’S FIVE FORCES ANALYSIS 66
5.7.1 INTENSITY OF COMPETITIVE RIVALRY 67
5.7.2 THREAT OF NEW ENTRANTS 67
5.7.3 THREAT OF SUBSTITUTES 68
5.7.4 BARGAINING POWER OF SUPPLIERS 68
5.7.5 BARGAINING POWER OF BUYERS 68
5.8 KEY STAKEHOLDERS & BUYING CRITERIA 69
5.8.1 KEY STAKEHOLDERS IN BUYING PROCESS 69
5.8.2 KEY BUYING CRITERIA 69
5.9 ECOSYSTEM ANALYSIS 70
5.10 VALUE CHAIN ANALYSIS 71
5.11 TARIFF & REGULATORY ANALYSIS 72
5.11.1 TARIFF DATA ANALYSIS 72
5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 72
5.11.3 REGULATORY LANDSCAPE 74
5.11.3.1 North America 74
5.11.3.1.1 US 74
5.11.3.2 Europe 75
5.11.3.3 Asia Pacific 75
5.11.3.3.1 Japan 75
5.11.3.3.2 China 76
5.11.3.3.3 India 77
5.12 PRICING ANALYSIS 78
5.12.1 AVERAGE SELLING PRICE OF SMART PILLS, BY KEY PLAYER, 2023 78
5.12.2 AVERAGE SELLING PRICE TREND FOR CAPSULE ENDOSCOPES, BY REGION, 2020–2023 79
5.13 CASE STUDY ANALYSIS 79
5.13.1 INCREASED IMAGING CAPABILITIES FOR PATIENTS WITH SMALL BOWEL ABNORMALITIES 79
5.13.2 DETECTION OF GASTRIC POLYP & ERYTHEMA THROUGH MAGNETICALLY CONTROLLED CAPSULE ENDOSCOPES 80
5.13.3 AI-ASSISTED CAPSULE ENDOSCOPY TO DETECT OBSCURE GASTROINTESTINAL BLEEDING IN HIGH-RISK CARDIAC PATIENTS 80
5.14 PATENT ANALYSIS 81
5.14.1 PATENT PUBLICATION TRENDS FOR SMART PILLS 81
5.14.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 82
5.14.3 LIST OF KEY PATENTS 83
5.15 KEY CONFERENCES & EVENTS, 2025–2026 84
5.16 UNMET NEEDS & END-USER EXPECTATIONS 85
5.16.1 UNMET NEEDS 85
5.16.2 END-USER EXPECTATIONS 86
5.17 TRADE ANALYSIS 87
5.18 INVESTMENT & FUNDING SCENARIO 88
5.19 BUSINESS MODEL ANALYSIS 88
5.19.1 DIRECT SALES TO HEALTHCARE PROVIDERS 88
5.19.2 SUBSCRIPTION-BASED SOFTWARE AND DATA ANALYTICS SERVICES 88
?
5.20 IMPACT OF AI/GEN AI ON SMART PILLS MARKET 88
5.20.1 KEY USE CASES 90
5.20.2 CASE STUDIES OF AI/GEN AI IMPLEMENTATION 90
5.20.2.1 CapsoCam SV-1 Versus PillCam SB3 to detect obscure gastrointestinal bleeding 90
5.20.2.2 AARDEX Group partnered with etectRx, Inc. to track medication-taking behaviors 91
5.20.3 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 92
5.20.3.1 AI in endoscopy 92
5.20.3.2 Wearable devices 92
5.20.3.3 Digital healthcare 93
5.20.3.4 Home healthcare 93
5.20.4 USER READINESS & IMPACT ASSESSMENT 93
5.20.4.1 User readiness 93
5.20.4.1.1 User A: Hospitals 93
5.20.4.1.2 User B: Diagnostic centers 93
5.20.4.2 Impact assessment 94
5.20.4.2.1 User A: Hospitals 94
5.20.4.2.1.1 Implementation 94
5.20.4.2.1.2 Impact 94
5.20.4.2.2 User B: Diagnostic centers 94
5.20.4.2.2.1 Implementation 94
5.20.4.2.2.2 Impact 95
6 SMART PILLS MARKET, BY TARGET AREA 96
6.1 INTRODUCTION 97
6.2 SMALL INTESTINE 97
6.2.1 COMPLEXITIES IN DIAGNOSIS AND MONITORING OF SMALL INTESTINE
TO AID ADOPTION OF SMART PILLS 97
6.3 LARGE INTESTINE 98
6.3.1 INCREASING INCIDENCE OF COLORECTAL CANCER TO SUPPORT MARKET GROWTH 98
6.4 ESOPHAGUS 99
6.4.1 HIGH PREVALENCE OF GASTROESOPHAGEAL REFLUX DISEASE AND BARRETT’S ESOPHAGUS TO AUGMENT MARKET GROWTH 99
6.5 STOMACH 100
6.5.1 IMPROVED DIAGNOSTIC ACCURACY AND EFFECTIVE PROXIMAL EXAMINATION SCOPE OF GASTRIC DISEASES TO DRIVE MARKET 100
7 SMART PILLS MARKET, BY APPLICATION 102
7.1 INTRODUCTION 103
7.2 CAPSULE ENDOSCOPY 103
7.2.1 INCREASED ABILITY TO ASSESS GASTROINTESTINAL BLEEDING AND SMALL BOWEL TUMORS TO DRIVE MARKET 103
7.3 PATIENT MONITORING 105
7.3.1 NEED FOR STREAMLINED INTEGRATION OF INNOVATIVE SENSOR TECHNOLOGIES TO DRIVE MARKET 105
7.4 TARGETED DRUG DELIVERY 106
7.4.1 SITE-SPECIFIC DRUG DELIVERY TO MINIMIZE DRUG DOSAGE
AND REDUCE HEALTHCARE COSTS 106
8 SMART PILLS MARKET, BY DISEASE INDICATION 108
8.1 INTRODUCTION 109
8.2 OCCULT GASTROINTESTINAL BLEEDING 109
8.2.1 IMPROVED DIAGNOSTIC ACCURACY TO FUEL UPTAKE OF SMART PILLS AS PATIENT-FRIENDLY ALTERNATIVE 109
8.3 CROHN’S DISEASE 110
8.3.1 TECHNOLOGICAL ADVANCEMENTS IN CAPSULE ENDOSCOPY TO BOOST ADOPTION OF SMART PILLS 110
8.4 CELIAC DISEASE 111
8.4.1 RISING INCIDENCE OF SMALL INTESTINE DISORDERS TO DRIVE MARKET 111
8.5 SMALL BOWEL TUMORS 112
8.5.1 GROWING DEMAND FOR NON-INVASIVE DIAGNOSTICS TO PROPEL MARKET GROWTH 112
8.6 OTHER DISEASE INDICATIONS 112
9 SMART PILLS MARKET, BY END USER 114
9.1 INTRODUCTION 115
9.2 HOSPITALS 115
9.2.1 INCREASING PREVALENCE OF INFLAMMATORY BOWEL DISEASE TO BOOST ADOPTION OF SMART PILLS IN HOSPITALS 115
9.3 DIAGNOSTIC CENTERS 116
9.3.1 BETTER PATIENT EXPERIENCE AND IMPROVED OPERATIONAL EFFICIENCY TO BOOST MARKET GROWTH 116
9.4 OUTPATIENT SETTINGS 117
9.4.1 NEED FOR ACCESSIBLE AND COST-EFFECTIVE CARE
TO SPUR MARKET GROWTH 117
9.5 OTHER END USERS 118
10 SMART PILLS MARKET, BY REGION 120
10.1 INTRODUCTION 121
10.2 NORTH AMERICA 122
10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 123
10.2.2 US 125
10.2.2.1 US to dominate North American smart pills market
during study period 125
10.2.3 CANADA 128
10.2.3.1 Rising incidence of IBD among geriatric population to
propel market growth 128
10.3 EUROPE 130
10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 130
10.3.2 GERMANY 132
10.3.2.1 Rising prevalence of Crohn’s disease to aid market growth 132
10.3.3 UK 134
10.3.3.1 Increasing prevalence of bowel cancer and colitis to
augment market growth 134
10.3.4 FRANCE 136
10.3.4.1 Favorable reimbursement coverage by government and third-party payers to aid market growth 136
10.3.5 ITALY 138
10.3.5.1 Growing adoption of capsule endoscopy for gastrointestinal diseases to propel market growth 138
10.3.6 SPAIN 140
10.3.6.1 Rising demand for non-invasive diagnostics to fuel uptake of smart pills 140
10.3.7 REST OF EUROPE 142
10.4 ASIA PACIFIC 144
10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 145
10.4.2 JAPAN 147
10.4.2.1 Increased prevalence of stomach cancer and favorable reimbursement scenario for capsule endoscopy to drive market 147
10.4.3 CHINA 150
10.4.3.1 Increasing geriatric population and rising incidence of gastric cancer to boost market growth 150
10.4.4 INDIA 152
10.4.4.1 Rising incidence of IBD and growing adoption of capsule endoscopy to support market growth 152
10.4.5 REST OF ASIA PACIFIC 154
10.5 LATIN AMERICA 156
10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 157
10.5.2 BRAZIL 159
10.5.2.1 Favorable government policies and presence of universal health coverage to aid market growth 159
10.5.3 MEXICO 161
10.5.3.1 Increased cancer awareness and favorable government initiatives to drive market 161
10.5.4 REST OF LATIN AMERICA 163
10.6 MIDDLE EAST & AFRICA 164
10.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 165
10.6.2 GCC COUNTRIES 167
10.6.2.1 Increased focus on healthcare infrastructure development and high R&D investment to support market growth 167
10.6.3 REST OF MIDDLE EAST & AFRICA 168
11 COMPETITIVE LANDSCAPE 171
11.1 INTRODUCTION 171
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 171
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN
SMART PILLS MARKET 171
11.3 REVENUE ANALYSIS, 2019–2023 174
11.4 MARKET SHARE ANALYSIS, 2023 175
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 176
11.5.1 STARS 176
11.5.2 EMERGING LEADERS 176
11.5.3 PERVASIVE PLAYERS 176
11.5.4 PARTICIPANTS 176
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 178
11.5.5.1 Company footprint 178
11.5.5.2 Region footprint 179
11.5.5.3 Application footprint 180
11.5.5.4 Target area footprint 181
11.5.5.5 Disease indication footprint 181
11.5.5.6 End-user footprint 182
11.5.5.7 Region footprint 183
11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 183
11.6.1 PROGRESSIVE COMPANIES 183
11.6.2 RESPONSIVE COMPANIES 183
11.6.3 DYNAMIC COMPANIES 183
11.6.4 STARTING BLOCKS 184
11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 185
11.6.5.1 Detailed list of key startups/SME players 185
11.6.5.2 Competitive benchmarking of key startups/SME players 186
11.7 COMPANY VALUATION & FINANCIAL METRICS 187
11.7.1 FINANCIAL METRICS 187
11.7.2 COMPANY VALUATION 187
11.8 BRAND/PRODUCT COMPARISON 188
11.9 COMPETITIVE SCENARIO 189
11.9.1 PRODUCT LAUNCHES, APPROVALS, AND ENHANCEMENTS 189
11.9.2 DEALS 190
11.9.3 OTHER DEVELOPMENTS 191
12 COMPANY PROFILES 192
12.1 KEY PLAYERS 192
12.1.1 MEDTRONIC 192
12.1.1.1 Business overview 192
12.1.1.2 Products/Services/Solutions offered 193
12.1.1.3 Recent developments 194
12.1.1.3.1 Product approvals & enhancements 194
12.1.1.3.2 Deals 194
12.1.1.4 MnM view 195
12.1.1.4.1 Right to win 195
12.1.1.4.2 Strategic choices 195
12.1.1.4.3 Weaknesses & competitive threats 195
12.1.2 OLYMPUS CORPORATION 196
12.1.2.1 Business overview 196
12.1.2.2 Products/Services/Solutions offered 197
12.1.2.3 Recent developments 198
12.1.2.3.1 Other developments 198
12.1.2.4 MnM view 198
12.1.2.4.1 Right to win 198
12.1.2.4.2 Strategic choices 198
12.1.2.4.3 Weaknesses & competitive threats 198
12.1.3 CAPSOVISION, INC. 199
12.1.3.1 Business overview 199
12.1.3.2 Products/Services/Solutions offered 199
12.1.3.3 Recent developments 200
12.1.3.3.1 Product approvals & enhancements 200
12.1.3.4 MnM view 201
12.1.3.4.1 Right to win 201
12.1.3.4.2 Strategic choices 201
12.1.3.4.3 Weaknesses & competitive threats 201
12.1.4 INTROMEDIC 202
12.1.4.1 Business overview 202
12.1.4.2 Products/Services/Solutions offered 202
12.1.4.3 MnM view 203
12.1.4.3.1 Right to win 203
12.1.4.3.2 Strategic choices 203
12.1.4.3.3 Weaknesses & competitive threats 203
12.1.5 JINSHAN SCIENCE & TECHNOLOGY 204
12.1.5.1 Business overview 204
12.1.5.2 Products/Services/Solutions offered 204
12.1.5.3 MnM view 205
12.1.5.3.1 Right to win 205
12.1.5.3.2 Strategic choices 205
12.1.5.3.3 Weaknesses & competitive threats 205
12.1.6 ANX ROBOTICS 206
12.1.6.1 Business overview 206
12.1.6.2 Products/Services/Solutions offered 206
12.1.6.3 Recent developments 207
12.1.6.3.1 Product launches, approvals, and enhancements 207
12.1.7 SHENZHEN JIFU MEDICAL TECHNOLOGY CO., LTD. 208
12.1.7.1 Business overview 208
12.1.7.2 Products/Services/Solutions offered 208
12.1.8 ETECTRX 209
12.1.8.1 Business overview 209
12.1.8.2 Products/Services/Solutions offered 209
12.1.8.3 Recent developments 210
12.1.8.3.1 Product enhancements 210
12.1.8.3.2 Deals 210
12.1.9 BODYCAP 211
12.1.9.1 Business overview 211
12.1.9.2 Products/Services/Solutions offered 211
12.1.9.3 Recent developments 212
12.1.9.3.1 Product launches 212
12.1.9.3.2 Deals 212
12.1.10 CHECK-CAP 213
12.1.10.1 Business overview 213
12.1.10.2 Products/Services/Solutions offered 213
12.1.10.3 Recent developments 214
12.1.10.3.1 Product approvals 214
12.1.10.3.2 Expansions 214
12.1.11 SHANGXIAN MINIMAL INVASIVE INC. 215
12.1.11.1 Business overview 215
12.1.11.2 Products/Services/Solutions offered 215
12.2 OTHER PLAYERS 216
12.2.1 VELOCE CORPORATION 216
12.2.2 BIOCAM 216
12.2.3 ENDIATX 217
12.2.4 RF CO., LTD. 217
12.2.5 CELERO SYSTEMS 218
12.2.6 BIORA THERAPEUTICS, INC. 218
12.2.7 INNURVATION 219
12.2.8 RANI THERAPEUTICS 220
12.2.9 MOTILIS MEDICA SA 221
?
13 APPENDIX 222
13.1 DISCUSSION GUIDE 222
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 226
13.3 CUSTOMIZATION OPTIONS 228
13.4 RELATED REPORTS 228
13.5 AUTHOR DETAILS 229



List of Figures

FIGURE 1 SMART PILLS MARKET SEGMENTATION & GEOGRAPHICAL SPREAD 26
FIGURE 2 SMART PILLS MARKET: YEARS CONSIDERED 28
FIGURE 3 SMART PILLS MARKET: RESEARCH DESIGN 30
FIGURE 4 SMART PILLS MARKET: KEY DATA FROM SECONDARY SOURCES 31
FIGURE 5 SMART PILLS MARKET: KEY PRIMARY SOURCES 32
FIGURE 6 SMART PILLS MARKET: KEY DATA FROM PRIMARY SOURCES 33
FIGURE 7 SMART PILLS MARKET: INSIGHTS FROM KEY PRIMARIES 33
FIGURE 8 BREAKDOWN OF PRIMARY EXPERTS: BY COMPANY TYPE DESIGNATION, AND REGION 34
FIGURE 9 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS 35
FIGURE 10 SMART PILLS MARKET: BOTTOM-UP APPROACH (DEMAND-SIDE ANALYSIS) 36
FIGURE 11 SMART PILLS MARKET: TOP-DOWN APPROACH 36
FIGURE 12 SMART PILLS MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2024–2030) 38
FIGURE 13 SMART PILLS MARKET: CAGR PROJECTIONS (SUPPLY SIDE) 38
FIGURE 14 SMART PILLS MARKET: DATA TRIANGULATION 40
FIGURE 15 SMART PILLS MARKET, BY APPLICATION, 2024 VS. 2030 (USD MILLION) 43
FIGURE 16 SMART PILLS MARKET, BY TARGET AREA, 2024 VS. 2030 (USD MILLION) 44
FIGURE 17 SMART PILLS MARKET, BY DISEASE INDICATION, 2024 VS. 2030 (USD MILLION) 44
FIGURE 18 SMART PILLS MARKET, BY END USER, 2024 VS. 2030 (USD MILLION) 45
FIGURE 19 REGIONAL SNAPSHOT OF SMART PILLS MARKET 45
FIGURE 20 INCREASING ADOPTION OF CAPSULE ENDOSCOPY IN EMERGING
ECONOMIES TO FUEL UPTAKE OF SMART PILLS 47
FIGURE 21 US AND CAPSULE ENDOSCOPY SEGMENTS DOMINATED NORTH AMERICAN SMART PILLS MARKET IN 2023 48
FIGURE 22 CHINA TO REGISTER HIGHEST GROWTH RATE FROM 2024 TO 2030 49
FIGURE 23 ASIA PACIFIC TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD 49
FIGURE 24 EMERGING MARKETS TO REGISTER HIGHEST
GROWTH RATE DURING STUDY PERIOD 50
FIGURE 25 SMART PILLS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 51
FIGURE 26 HEALTHCARE SECURITY BREACHES OF 500 + RECORDS, 2009–2024 57
FIGURE 27 SMART PILLS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 63
FIGURE 28 SMART PILLS MARKET: PORTER’S FIVE FORCES ANALYSIS 67
FIGURE 29 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY APPLICATION 69
FIGURE 30 KEY BUYING CRITERIA FOR SMART PILLS, BY APPLICATION 69
FIGURE 31 SMART PILLS MARKET: ECOSYSTEM ANALYSIS 70
FIGURE 32 SMART PILLS MARKET: VALUE CHAIN ANALYSIS 71
FIGURE 33 AVERAGE SELLING PRICE OF SMART PILLS, BY KEY PLAYER (2023) 78
FIGURE 34 SMART PILLS MARKET: GLOBAL PATENT PUBLICATION TRENDS (2015–2024) 81
FIGURE 35 TOP APPLICANTS (COMPANIES/INSTITUTIONS) FOR SMART PILL PATENTS (JANUARY 2014–DECEMBER 2024) 82
FIGURE 36 TOP APPLICANTS FOR SMART PILL PATENTS (COUNTRY/REGION)
(JANUARY 2014–DECEMBER 2024) 83
FIGURE 37 SMART PILLS MARKET: FUNDING AND NUMBER OF DEALS (2020–2024) 88
FIGURE 38 MARKET POTENTIAL OF AI/GEN AI ON SMART PILLS ACROSS INDUSTRIES 89
FIGURE 39 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 92
FIGURE 40 NORTH AMERICA: SMART PILLS MARKET SNAPSHOT 123
FIGURE 41 ASIA PACIFIC: SMART PILLS MARKET SNAPSHOT 145
FIGURE 42 REVENUE ANALYSIS OF KEY PLAYERS IN SMART PILLS MARKET 2019–2023 (USD MILLION) 174
FIGURE 43 MARKET SHARE ANALYSIS OF KEY PLAYERS IN SMART PILLS MARKET (2023) 175
FIGURE 44 SMART PILLS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023 177
FIGURE 45 SMART PILLS MARKET: COMPANY FOOTPRINT 178
FIGURE 46 SMART PILLS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 184
FIGURE 47 EV/EBITDA OF KEY VENDORS 187
FIGURE 48 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA
OF KEY VENDORS 187
FIGURE 49 SMART PILLS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 188
FIGURE 50 MEDTRONIC: COMPANY SNAPSHOT 193
FIGURE 51 OLYMPUS CORPORATION: COMPANY SNAPSHOT 197

List of Tables

TABLE 1 SMART PILLS MARKET: INCLUSIONS & EXCLUSIONS 27
TABLE 2 SMART PILLS MARKET: STUDY ASSUMPTIONS 41
TABLE 3 SMART PILLS MARKET: RISK ANALYSIS 41
TABLE 4 SMART PILLS MARKET: IMPACT ANALYSIS 52
TABLE 5 SENSOR AND BATTERY TYPES FOR CAPSULE ENDOSCOPY PRODUCTS 61
TABLE 6 SENSORS USED FOR VITAL SIGN MONITORING PRODUCTS 62
TABLE 7 SMART PILLS MARKET: DRUGS UNDER PIPELINE 64
TABLE 8 SMART PILLS MARKET: PORTER’S FIVE FORCES ANALYSIS 66
TABLE 9 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY APPLICATION (%) 69
TABLE 10 KEY BUYING CRITERIA FOR SMART PILLS, BY APPLICATION 70
TABLE 11 TARIFF DATA FOR HS CODE 901890 72
TABLE 12 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS 72
TABLE 13 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS 73
TABLE 14 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS 73
TABLE 15 US FDA: MEDICAL DEVICE CLASSIFICATION 74
TABLE 16 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 74
TABLE 17 EUROPE: LEVEL OF RISK, TIME, COST, AND COMPLEXITY OF
REGISTRATION PROCESS 75
TABLE 18 JAPAN: MEDICAL DEVICES CLASSIFICATION UNDER PMDA 76
TABLE 19 CHINA: CLASSIFICATION UNDER CLASS I/II/III MEDICAL DEVICES 76
TABLE 20 INDIA: LEVEL OF RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 77
TABLE 21 AVERAGE SELLING PRICE OF CAPSULE ENDOSCOPES, BY KEY PLAYER, 2023 (USD) 78
TABLE 22 AVERAGE SELLING PRICE TREND OF CAPSULE ENDOSCOPES, BY REGION, 2020–2023 (USD PER UNIT) 79
TABLE 23 CASE STUDY 1: INCREASED IMAGING CAPABILITIES FOR PATIENTS WITH SMALL BOWEL ABNORMALITIES 79
TABLE 24 CASE STUDY 2: DETECTION OF GASTRIC POLYP & ERYTHEMA THROUGH MAGNETICALLY CONTROLLED CAPSULE ENDOSCOPES 80
TABLE 25 CASE STUDY 3: AI-ASSISTED CAPSULE ENDOSCOPY TO DETECT OBSCURE GASTROINTESTINAL BLEEDING IN HIGH-RISK CARDIAC PATIENTS 80
TABLE 26 SMART PILLS MARKET: LIST OF KEY PATENTS, JANUARY 2020–DECEMBER 2024 83
TABLE 27 SMART PILLS MARKET: LIST OF KEY CONFERENCES & EVENTS JANUARY 2025–DECEMBER 2026 84
TABLE 28 SMART PILLS MARKET: UNMET NEEDS 85
TABLE 29 SMART PILLS MARKET: END-USER EXPECTATIONS 86
TABLE 30 TOP 10 IMPORTERS FOR HSN CODE 901890, BY COUNTRY 2020?2023 (USD THOUSAND) 87
TABLE 31 TOP 10 EXPORTERS FOR HSN CODE 901890, BY COUNTRY 2020?2023 (USD THOUSAND) 87
TABLE 32 CASE STUDY 1: CAPSOCAM SV-1 VERSUS PILLCAM SB3 TO DETECT OBSCURE GASTROINTESTINAL BLEEDING 90
TABLE 33 CASE STUDY 2: AARDEX GROUP PARTNERED WITH ETECTRX, INC. TO TRACK MEDICATION-TAKING BEHAVIORS 91
TABLE 34 SMART PILLS MARKET, BY TARGET AREA, 2022–2030 (USD MILLION) 97
TABLE 35 SMART PILLS MARKET FOR SMALL INTESTINE, BY REGION 2022–2030 (USD MILLION) 98
TABLE 36 SMART PILLS MARKET FOR LARGE INTESTINE, BY REGION 2022–2030 (USD MILLION) 99
TABLE 37 SMART PILLS MARKET FOR ESOPHAGUS, BY REGION, 2022–2030 (USD MILLION) 100
TABLE 38 SMART PILLS MARKET FOR STOMACH, BY REGION, 2022–2030 (USD MILLION) 101
TABLE 39 SMART PILLS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 103
TABLE 40 KEY CAPSULE ENDOSCOPES OFFERED BY MAJOR MARKET PLAYERS 104
TABLE 41 SMART PILLS MARKET FOR CAPSULE ENDOSCOPY, BY REGION 2022–2030 (USD MILLION) 104
TABLE 42 KEY PATIENT MONITORING SMART PILLS OFFERED BY MAJOR MARKET PLAYERS 105
TABLE 43 SMART PILLS MARKET FOR PATIENT MONITORING, BY REGION 2022–2030 (USD MILLION) 106
TABLE 44 KEY TARGETED DRUG DELIVERY SMART PILLS UNDER PIPELINE 107
TABLE 45 SMART PILLS MARKET FOR TARGETED DRUG DELIVERY, BY REGION 2022–2030 (USD MILLION) 107
TABLE 46 SMART PILLS MARKET, BY DISEASE INDICATION, 2022–2030 (USD MILLION) 109
TABLE 47 SMART PILLS MARKET FOR OCCULT GASTROINTESTINAL BLEEDING, BY REGION, 2022–2030 (USD MILLION) 110
TABLE 48 SMART PILLS MARKET FOR CROHN’S DISEASE, BY REGION 2022–2030 (USD MILLION) 111
TABLE 49 SMART PILLS MARKET FOR CELIAC DISEASE, BY REGION 2022–2030 (USD MILLION) 111
TABLE 50 SMART PILLS MARKET FOR SMALL BOWEL TUMORS, BY REGION 2022–2030 (USD MILLION) 112
TABLE 51 SMART PILLS MARKET FOR OTHER DISEASE INDICATIONS, BY REGION 2022–2030 (USD MILLION) 113
TABLE 52 SMART PILLS MARKET, BY END USER, 2022–2030 (USD MILLION) 115
TABLE 53 SMART PILLS MARKET FOR HOSPITALS, BY REGION, 2022–2030 (USD MILLION) 116
TABLE 54 SMART PILLS MARKET FOR DIAGNOSTIC CENTERS, BY REGION 2022–2030 (USD MILLION) 117
TABLE 55 SMART PILLS MARKET FOR OUTPATIENT SETTINGS, BY REGION 2022–2030 (USD MILLION) 118
TABLE 56 SMART PILLS MARKET FOR OTHER END USERS, BY REGION 2022–2030 (USD MILLION) 119
TABLE 57 SMART PILLS MARKET, BY REGION, 2022–2030 (USD MILLION) 121
TABLE 58 SMART PILLS MARKET FOR CAPSULE ENDOSCOPY, BY REGION 2022–2030 (THOUSAND UNITS) 121
TABLE 59 SMART PILLS MARKET FOR PATIENT MONITORING, BY REGION 2022–2030 (THOUSAND UNITS) 122
TABLE 60 NORTH AMERICA: SMART PILLS MARKET, BY COUNTRY 2022–2030 (USD MILLION) 124
TABLE 61 NORTH AMERICA: SMART PILLS MARKET, BY TARGET AREA 2022–2030 (USD MILLION) 124
TABLE 62 NORTH AMERICA: SMART PILLS MARKET, BY APPLICATION 2022–2030 (USD MILLION) 124
TABLE 63 NORTH AMERICA: SMART PILLS MARKET, BY DISEASE INDICATION 2022–2030 (USD MILLION) 125
TABLE 64 NORTH AMERICA: SMART PILLS MARKET, BY END USER 2022–2030 (USD MILLION) 125
TABLE 65 US: KEY MACROINDICATORS 126
TABLE 66 US: SMART PILLS MARKET, BY TARGET AREA, 2022–2030 (USD MILLION) 127
TABLE 67 US: SMART PILLS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 127
TABLE 68 US: SMART PILLS MARKET, BY DISEASE INDICATION, 2022–2030 (USD MILLION) 127
TABLE 69 US: SMART PILLS MARKET, BY END USER, 2022–2030 (USD MILLION) 128
TABLE 70 CANADA: KEY MACROINDICATORS 128
TABLE 71 CANADA: SMART PILLS MARKET, BY TARGET AREA, 2022–2030 (USD MILLION) 129
TABLE 72 CANADA: SMART PILLS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 129
TABLE 73 CANADA: SMART PILLS MARKET, BY DISEASE INDICATION 2022–2030 (USD MILLION) 129
TABLE 74 CANADA: SMART PILLS MARKET, BY END USER, 2022–2030 (USD MILLION) 130
TABLE 75 EUROPE: SMART PILLS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 131
TABLE 76 EUROPE: SMART PILLS MARKET, BY TARGET AREA, 2022–2030 (USD MILLION) 131
TABLE 77 EUROPE: SMART PILLS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 131
TABLE 78 EUROPE: SMART PILLS MARKET, BY DISEASE INDICATION 2022–2030 (USD MILLION) 132
TABLE 79 EUROPE: SMART PILLS MARKET, BY END USER, 2022–2030 (USD MILLION) 132
TABLE 80 GERMANY: KEY MACROINDICATORS 133
TABLE 81 GERMANY: SMART PILLS MARKET, BY TARGET AREA, 2022–2030 (USD MILLION) 133
TABLE 82 GERMANY: SMART PILLS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 133
TABLE 83 GERMANY: SMART PILLS MARKET, BY DISEASE INDICATION 2022–2030 (USD MILLION) 134
TABLE 84 GERMANY: SMART PILLS MARKET, BY END USER, 2022–2030 (USD MILLION) 134
TABLE 85 UK: KEY MACROINDICATORS 135
TABLE 86 UK: SMART PILLS MARKET, BY TARGET AREA, 2022–2030 (USD MILLION) 135
TABLE 87 UK: SMART PILLS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 135
TABLE 88 UK: SMART PILLS MARKET, BY DISEASE INDICATION, 2022–2030 (USD MILLION) 136
TABLE 89 UK: SMART PILLS MARKET, BY END USER, 2022–2030 (USD MILLION) 136
TABLE 90 FRANCE: KEY MACROINDICATORS 137
TABLE 91 FRANCE: SMART PILLS MARKET, BY TARGET AREA, 2022–2030 (USD MILLION) 137
TABLE 92 FRANCE: SMART PILLS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 137
TABLE 93 FRANCE: SMART PILLS MARKET, BY DISEASE INDICATION 2022–2030 (USD MILLION) 138
TABLE 94 FRANCE: SMART PILLS MARKET, BY END USER, 2022–2030 (USD MILLION) 138
TABLE 95 ITALY: KEY MACROINDICATORS 139
TABLE 96 ITALY: SMART PILLS MARKET, BY TARGET AREA, 2022–2030 (USD MILLION) 139
TABLE 97 ITALY: SMART PILLS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 139
TABLE 98 ITALY: SMART PILLS MARKET, BY DISEASE INDICATION 2022–2030 (USD MILLION) 140
TABLE 99 ITALY: SMART PILLS MARKET, BY END USER, 2022–2030 (USD MILLION) 140
TABLE 100 SPAIN: KEY MACROINDICATORS 141
TABLE 101 SPAIN: SMART PILLS MARKET, BY TARGET AREA, 2022–2030 (USD MILLION) 141
TABLE 102 SPAIN: SMART PILLS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 141
TABLE 103 SPAIN: SMART PILLS MARKET, BY DISEASE INDICATION 2022–2030 (USD MILLION) 142
TABLE 104 SPAIN: SMART PILLS MARKET, BY END USER, 2022–2030 (USD MILLION) 142
TABLE 105 REST OF EUROPE: SMART PILLS MARKET, BY TARGET AREA 2022–2030 (USD MILLION) 143
TABLE 106 REST OF EUROPE: SMART PILLS MARKET, BY APPLICATION 2022–2030 (USD MILLION) 143
TABLE 107 REST OF EUROPE: SMART PILLS MARKET, BY DISEASE INDICATION 2022–2030 (USD MILLION) 143
TABLE 108 REST OF EUROPE: SMART PILLS MARKET, BY END USER 2022–2030 (USD MILLION) 144
TABLE 109 ASIA PACIFIC: SMART PILLS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 146
TABLE 110 ASIA PACIFIC: SMART PILLS MARKET, BY TARGET AREA 2022–2030 (USD MILLION) 146
TABLE 111 ASIA PACIFIC: SMART PILLS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 146
TABLE 112 ASIA PACIFIC: SMART PILLS MARKET, BY DISEASE INDICATION 2022–2030 (USD MILLION) 147
TABLE 113 ASIA PACIFIC: SMART PILLS MARKET, BY END USER, 2022–2030 (USD MILLION) 147
TABLE 114 JAPAN: KEY MACROINDICATORS 148
TABLE 115 JAPAN: SMART PILLS MARKET, BY TARGET AREA, 2022–2030 (USD MILLION) 148
TABLE 116 JAPAN: SMART PILLS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 149
TABLE 117 JAPAN: SMART PILLS MARKET, BY DISEASE INDICATION 2022–2030 (USD MILLION) 149
TABLE 118 JAPAN: SMART PILLS MARKET, BY END USER, 2022–2030 (USD MILLION) 149
TABLE 119 CHINA: KEY MACROINDICATORS 150
TABLE 120 CHINA: SMART PILLS MARKET, BY TARGET AREA, 2022–2030 (USD MILLION) 151
TABLE 121 CHINA: SMART PILLS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 151
TABLE 122 CHINA: SMART PILLS MARKET, BY DISEASE INDICATION 2022–2030 (USD MILLION) 151
TABLE 123 CHINA: SMART PILLS MARKET, BY END USER, 2022–2030 (USD MILLION) 152
TABLE 124 INDIA: KEY MACROINDICATORS 153
TABLE 125 INDIA: SMART PILLS MARKET, BY TARGET AREA, 2022–2030 (USD MILLION) 153
TABLE 126 INDIA: SMART PILLS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 153
TABLE 127 INDIA: SMART PILLS MARKET, BY DISEASE INDICATION 2022–2030 (USD MILLION) 154
TABLE 128 INDIA: SMART PILLS MARKET, BY END USER, 2022–2030 (USD MILLION) 154
TABLE 129 REST OF ASIA PACIFIC: SMART PILLS MARKET, BY TARGET AREA 2022–2030 (USD MILLION) 155
TABLE 130 REST OF ASIA PACIFIC: SMART PILLS MARKET, BY APPLICATION 2022–2030 (USD MILLION) 155
TABLE 131 REST OF ASIA PACIFIC: SMART PILLS MARKET, BY DISEASE INDICATION 2022–2030 (USD MILLION) 156
TABLE 132 REST OF ASIA PACIFIC: SMART PILLS MARKET, BY END USER 2022–2030 (USD MILLION) 156
TABLE 133 LATIN AMERICA: SMART PILLS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 157
TABLE 134 LATIN AMERICA: SMART PILLS MARKET, BY TARGET AREA 2022–2030 (USD MILLION) 157
TABLE 135 LATIN AMERICA: SMART PILLS MARKET, BY APPLICATION 2022–2030 (USD MILLION) 158
TABLE 136 LATIN AMERICA: SMART PILLS MARKET, BY DISEASE INDICATION 2022–2030 (USD MILLION) 158
TABLE 137 LATIN AMERICA: SMART PILLS MARKET, BY END USER 2022–2030 (USD MILLION) 158
TABLE 138 BRAZIL: KEY MACROINDICATORS 159
TABLE 139 BRAZIL: SMART PILLS MARKET, BY TARGET AREA, 2022–2030 (USD MILLION) 159
TABLE 140 BRAZIL: SMART PILLS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 160
TABLE 141 BRAZIL: SMART PILLS MARKET, BY DISEASE INDICATION 2022–2030 (USD MILLION) 160
TABLE 142 BRAZIL: SMART PILLS MARKET, BY END USER, 2022–2030 (USD MILLION) 160
TABLE 143 MEXICO: KEY MACROINDICATORS 161
TABLE 144 MEXICO: SMART PILLS MARKET, BY TARGET AREA, 2022–2030 (USD MILLION) 161
TABLE 145 MEXICO: SMART PILLS MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 162
TABLE 146 MEXICO: SMART PILLS MARKET, BY DISEASE INDICATION 2022–2030 (USD MILLION) 162
TABLE 147 MEXICO: SMART PILLS MARKET, BY END USER, 2022–2030 (USD MILLION) 162
TABLE 148 REST OF LATIN AMERICA: SMART PILLS MARKET, BY TARGET AREA 2022–2030 (USD MILLION) 163
TABLE 149 REST OF LATIN AMERICA: SMART PILLS MARKET, BY APPLICATION 2022–2030 (USD MILLION) 163
TABLE 150 REST OF LATIN AMERICA: SMART PILLS MARKET, BY DISEASE INDICATION 2022–2030 (USD MILLION) 164
TABLE 151 REST OF LATIN AMERICA: SMART PILLS MARKET, BY END USER 2022–2030 (USD MILLION) 164
TABLE 152 MIDDLE EAST & AFRICA: SMART PILLS MARKET, BY REGION 2022–2030 (USD MILLION) 165
TABLE 153 MIDDLE EAST & AFRICA: SMART PILLS MARKET, BY TARGET AREA 2022–2030 (USD MILLION) 165
TABLE 154 MIDDLE EAST & AFRICA: SMART PILLS MARKET, BY APPLICATION 2022–2030 (USD MILLION) 166
TABLE 155 MIDDLE EAST & AFRICA: SMART PILLS MARKET, BY DISEASE INDICATION 2022–2030 (USD MILLION) 166
TABLE 156 MIDDLE EAST & AFRICA: SMART PILLS MARKET, BY END USER 2022–2030 (USD MILLION) 166
TABLE 157 GCC COUNTRIES: SMART PILLS MARKET, BY TARGET AREA 2022–2030 (USD MILLION) 167
TABLE 158 GCC COUNTRIES: SMART PILLS MARKET, BY APPLICATION 2022–2030 (USD MILLION) 167
TABLE 159 GCC COUNTRIES: SMART PILLS MARKET, BY DISEASE INDICATION 2022–2030 (USD MILLION) 168
TABLE 160 GCC COUNTRIES: SMART PILLS MARKET, BY END USER 2022–2030 (USD MILLION) 168
TABLE 161 REST OF MIDDLE EAST & AFRICA: SMART PILLS MARKET, BY TARGET AREA 2022–2030 (USD MILLION) 169
TABLE 162 REST OF MIDDLE EAST & AFRICA: SMART PILLS MARKET, BY APPLICATION 2022–2030 (USD MILLION) 169
TABLE 163 REST OF MIDDLE EAST & AFRICA: SMART PILLS MARKET, BY DISEASE INDICATION, 2022–2030 (USD MILLION) 169
TABLE 164 REST OF MIDDLE EAST & AFRICA: SMART PILLS MARKET, BY END USER 2022–2030 (USD MILLION) 170
TABLE 165 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN SMART PILLS MARKET, JANUARY 2021–JANUARY 2025 171
TABLE 166 SMART PILLS MARKET: DEGREE OF COMPETITION 175
TABLE 167 SMART PILLS MARKET: REGION FOOTPRINT 179
TABLE 168 SMART PILLS MARKET: APPLICATION FOOTPRINT 180
TABLE 169 SMART PILLS MARKET: TARGET AREA FOOTPRINT 181
TABLE 170 SMART PILLS MARKET: DISEASE INDICATION FOOTPRINT 181
TABLE 171 SMART PILLS MARKET: END-USER FOOTPRINT 182
TABLE 172 SMART PILLS MARKET: REGION FOOTPRINT 183
TABLE 173 SMART PILLS MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS 185
TABLE 174 SMART PILLS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS 186
TABLE 175 SMART PILLS MARKET: PRODUCT LAUNCHES, APPROVALS, AND ENHANCEMENTS, JANUARY 2021–JANUARY 2025 189
TABLE 176 SMART PILLS MARKET: DEALS, JANUARY 2021–JANUARY 2025 190
TABLE 177 SMART PILLS MARKET: OTHER DEVELOPMENTS, JANUARY 2021–JANUARY 2025 191
TABLE 178 MEDTRONIC: COMPANY OVERVIEW 192
TABLE 179 MEDTRONIC: PRODUCTS/SERVICES/SOLUTIONS OFFERED 193
TABLE 180 MEDTRONIC: PRODUCT APPROVALS & ENHANCEMENTS JANUARY 2021–JANUARY 2025 194
TABLE 181 MEDTRONIC: DEALS, JANUARY 2021–JANUARY 2025 194
TABLE 182 OLYMPUS CORPORATION: COMPANY OVERVIEW 196
TABLE 183 OLYMPUS CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED 197
TABLE 184 OLYMPUS CORPORATION: OTHER DEVELOPMENTS JANUARY 2021–JANUARY 2025 198
TABLE 185 CAPSOVISION, INC.: COMPANY OVERVIEW 199
TABLE 186 CAPSOVISION, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 199
TABLE 187 CAPSOVISION, INC.: PRODUCT APPROVALS & ENHANCEMENTS, JANUARY 2021–JANUARY 2025 200
TABLE 188 INTROMEDIC: COMPANY OVERVIEW 202
TABLE 189 INTROMEDIC: PRODUCTS/SERVICES/SOLUTIONS OFFERED 202
TABLE 190 JINSHAN SCIENCE & TECHNOLOGY: COMPANY OVERVIEW 204
TABLE 191 JINSHAN SCIENCE & TECHNOLOGY: PRODUCTS/SERVICES/SOLUTIONS OFFERED 204
TABLE 192 ANX ROBOTICS: COMPANY OVERVIEW 206
TABLE 193 ANX ROBOTICS: PRODUCTS/SERVICES/SOLUTIONS OFFERED 206
TABLE 194 ANX ROBOTICS: PRODUCT LAUNCHES, APPROVALS, AND ENHANCEMENTS, JANUARY 2021–JANUARY 2025 207
TABLE 195 SHENZHEN JIFU MEDICAL TECHNOLOGY CO., LTD.: COMPANY OVERVIEW 208
TABLE 196 SHENZHEN JIFU MEDICAL TECHNOLOGY CO., LTD.: PRODUCTS/SERVICES/ SOLUTIONS OFFERED 208
TABLE 197 ETECTRX: COMPANY OVERVIEW 209
TABLE 198 ETECTRX: PRODUCTS/SERVICES/SOLUTIONS OFFERED 209
TABLE 199 ETECTRX: PRODUCT ENHANCEMENTS, JANUARY 2021–JANUARY 2025 210
TABLE 200 ETECTRX: DEALS, JANUARY 2021–JANUARY 2025 210
TABLE 201 BODYCAP: COMPANY OVERVIEW 211
TABLE 202 BODYCAP: PRODUCTS/SERVICES/SOLUTIONS OFFERED 211
TABLE 203 BODYCAP: PRODUCT LAUNCHES, JANUARY 2021–JANUARY 2025 212
TABLE 204 BODYCAP: DEALS, JANUARY 2021–JANUARY 2025 212
TABLE 205 CHECK-CAP: COMPANY OVERVIEW 213
TABLE 206 CHECK-CAP: PRODUCTS/SERVICES/SOLUTIONS OFFERED 213
TABLE 207 CHECK-CAP: PRODUCT APPROVALS, JANUARY 2021–JANUARY 2025 214
TABLE 208 CHECK-CAP: EXPANSIONS, JANUARY 2021–JANUARY 2025 214
TABLE 209 SHANGXIAN MINIMAL INVASIVE INC.: COMPANY OVERVIEW 215
TABLE 210 SHANGXIAN MINIMAL INVASIVE INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 215
TABLE 211 VELOCE CORPORATION: COMPANY OVERVIEW 216
TABLE 212 BIOCAM: COMPANY OVERVIEW 216
TABLE 213 ENDIATX: COMPANY OVERVIEW 217
TABLE 214 RF CO., LTD.: COMPANY OVERVIEW 217
TABLE 215 CELERO SYSTEMS: COMPANY OVERVIEW 218
TABLE 216 BIORA THERAPEUTICS, INC.: COMPANY OVERVIEW 218
TABLE 217 INNURVATION: COMPANY OVERVIEW 219
TABLE 218 RANI THERAPEUTICS: COMPANY OVERVIEW 220
TABLE 219 MOTILIS MEDICA SA: COMPANY OVERVIEW 221